Thelansis

  Chronic Granulomatous Disease (CGD) Market Outlook Thelansis’s “Chronic Granulomatous Disease (CGD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Granulomatous Disease (CGD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Chronic Granulomatous Disease (CGD) Overview Chronic granulomatous disease (CGD) is a primary immunodeficiency disorder characterized by an increased susceptibility to severe bacterial and fungal infections. This condition arises due to a deficiency in the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase enzyme within the phagocytes of affected individuals, impairing their ability to pro...

  Chronic granulomatous disease (CGD) is a primary immunodeficiency disorder marked by a heightened susceptibility to severe bacterial and fungal infections. This condition arises due to a deficiency in the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase enzyme within the phagocytes of affected individuals, impairing their ability to produce superoxide. Clinically, CGD is characterized by recurrent infections primarily caused by a limited spectrum of pathogens, including Staphylococcus aureus, Aspergillus species, Klebsiella species, Burkholderia cepacia, Serratia marcescens, and Salmonella species. Additionally, patients often experience inflammatory complications, such as inflammatory bowel disease. Management of CGD involves preventive strategies such as antibacterial prophylaxis with trimethoprim-sulfamethoxazole and antifungal prophylaxis, typically with itraconazole. Furthermore, interferon-gamma immunotherapy has shown efficacy in reducing the frequency of...